Component
Bortezomib-mediated proteasome inhibition
Study-scoped entity; inspect species, exposure, model and limitations on each claim.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
Direct EGCG–bortezomib reaction prevented proteasome inhibition and downstream stress/death responses; tested nonboronic inhibitors did not show the same antagonism.
Experimental context and source evidence
- experimental_model
- Myeloma/glioblastoma cell experiments and animal models in the 2009 Blood study.
- limitations
- Preclinical findings; no human coadministration outcome trial. Chemical form and simultaneous concentrations matter.
- nutrient_topic
- EGCG collection; comparator and shared-pathway records retain their actual intervention. · Epigallocatechin-3-gallate (EGCG)
- plain_language
- The proposed interference starts with drug chemistry.
- primary_references
- Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. · 2009 · https://pubmed.ncbi.nlm.nih.gov/19190249/ · DOI 10.1182/blood-2008-07-171389
EGCG: receptor signaling, metabolism, nutrient interactions and discovery questions (2026-09-18) · lines 404–410
AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Myeloma/glioblastoma cell experiments and animal models in the 2009 Blood study. · source_derived_draft · unverified_draft
## egcg-bortezomib-proteasome The proposed interference starts with drug chemistry. Direct EGCG–bortezomib reaction prevented proteasome inhibition and downstream stress/death responses; tested nonboronic inhibitors did not show the same antagonism. Model: Myeloma/glioblastoma cell experiments and animal models in the 2009 Blood study. Limitations: Preclinical findings; no human coadministration outcome trial. Chemical form and simultaneous concentrations matter. Evidence access: primary abstract. Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors. · 2009 · https://pubmed.ncbi.nlm.nih.gov/19190249/ · DOI 10.1182/blood-2008-07-171389
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.